Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-04-08
2008-04-08
Haddad, Maher M. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387700
Reexamination Certificate
active
10754922
ABSTRACT:
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
REFERENCES:
patent: 4752601 (1988-06-01), Hahn
patent: 5348876 (1994-09-01), Michaelson et al.
patent: 5576184 (1996-11-01), Better et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5698449 (1997-12-01), Baumann et al.
patent: 5723584 (1998-03-01), Schatz
patent: 5736135 (1998-04-01), Goeddel et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5874239 (1999-02-01), Schatz
patent: 5932433 (1999-08-01), Schatz
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6025485 (2000-02-01), Kamb et al.
patent: 6114147 (2000-09-01), Frenken et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6242195 (2001-06-01), Idusogie et al.
patent: 6277375 (2001-08-01), Ward
patent: 6300065 (2001-10-01), Kieke et al.
patent: 6423538 (2002-07-01), Wittrup et al.
patent: 6455263 (2002-09-01), Payan
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6737056 (2004-05-01), Presta
patent: 6821505 (2004-11-01), Ward
patent: 2003/0158389 (2003-08-01), Idusogie et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0110226 (2004-06-01), Lazar et al.
patent: 2004/0132101 (2004-07-01), Lazar et al.
patent: 2004/0185045 (2004-09-01), Koenig et al.
patent: 2005/0054832 (2005-03-01), Lazar et al.
patent: 0 327 378 (1989-08-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 89/07142 (1989-08-01), None
patent: WO 92/16562 (1992-10-01), None
patent: WO 93/22332 (1993-11-01), None
patent: WO 94/18330 (1994-08-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 95/05468 (1995-02-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/44362 (1997-11-01), None
patent: WO 98/05787 (1998-02-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 98/52975 (1998-11-01), None
patent: WO 99/43713 (1999-09-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 02/060919 (2002-08-01), None
patent: WO 02/086070 (2002-10-01), None
patent: WO 03/074679 (2003-09-01), None
patent: WO 2004/029207 (2004-04-01), None
patent: WO 2004/074455 (2004-09-01), None
patent: WO 2004/099249 (2004-11-01), None
patent: WO 2005/070963 (2005-08-01), None
patent: WO 2006/020114 (2006-02-01), None
US 6,331,391, 12/2001, Wittrup et al. (withdrawn)
Vietta et al. Science 2006 313:308-309.
Altman et al., Phenotypic Analysis of Antigen-Specific T Lymphocytes, Science 274:94-96, 1996.
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol Immunol 30 :105-108, 1993.
Armour et al., “The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors,” Biochemical Society Transactions 30:495-500, 2002.
Armour et al., “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,” Eur J Immunol 29:2613-2624, 1999.
Armour et al., “Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies,” Mol Immunol 40 :585-593, 2003.
Armstrong, S. et al. “Heterogeneity of IgG1 monoclonal anti-Rh(D): an investigation using ADCC and macrophage binding assays,” Brit. J. Haematol. 66:257-262 (1987).
Baggiolini M, Dewald B. “Cellular models for the detection and evaluation of drugs that modulate human phagocyte activity,” Experientia. Oct. 15;44(10):841-848, 1988.
Boder and Wittrup, 1997, “Yeast surface display for screening combinatorial polypeptide libraries”, Nature Biotechnology 15:553-557.
Boder and Wittrup, “Optimal screening of surface-displayed polypeptide libraries,” Biotechnol Prog 14:55-62, 1998.
Boder and Wittrup, “Yeast surface display for directed evolution of protein expression, affinity, and stability,” Methods in Enzymology 328:430-444, 2000.
Boder et al., “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity,” Proc. Natl. Acad. Sci. USA 97:10701-10705, 2000.
Bredius et al., “Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes,” Immunology 83:624-630, 1994.
Brekke et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis.,” Eur J Immunol 24:2542-2547, 1994.
Brown EJ., vol. 45 (Microbes as Tools for Cell Biology) inMethods In Cell Biololgy, Russell ed. Academic Press Inc. pp. 147-164, 1994.
Burlmeister et al., “Crystal structure of the complex on rat neonatal Fc receptor with Fc,” Nature 372:379-383, 1994.
Burton and Woof, “Human antibody effector function,” Advances in Immunology 51:1-84, 1992.
Burton et al., “Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI),” Mol Immunol 25:1175-1181, 1988.
Burton, “Immunoglobulin G: functional sites,” Mol Immunol 22:161-206, 1985.
Canfield and Morrison, “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in CH2 domain and is modulated by the hinge region,” J Exp Med 173:1483-1491, 1991.
Caron et al., “Engineered humanized dimeric forms of IgG are more effective antibodies,” J Exp Med 176 :1191-5, 1992.
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc. Natl. Acad. Sci. USA 89:4285-4289, 1992.
Cartron et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIA gene,” Blood 99 :754-758, 2002.
Chappel et al., “Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies,” Proc. Natl. Acad. Sci USA 88:9036-9040, 1991.
Chappel et al., “Identification of a secondary Fc gamma RI binding site within a genetically engineered human IgG antibody,” J Biol. Chem 268:25124-25131, 1993.
Ciccimarra et al., “Localization of the IgG effector site for monocyte receptors,” Proc. Natl. Acad. Sci. U.S.A. 72 :2081-2083, 1975.
Clynes and Ravetch, “Cytotoxic antibodies trigger inflammation through Fc receptors,” Immunity 3:21-26, 1995.
Clynes et al., “Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors,” J Exp Med 189:179-185, 1999.
Clynes et al., “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nature Medicine 6 :443-446, 2000.
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc. Natl. Acad. Sci USA 95:652-656, 1998.
Clynes et al., “Uncoupling of immu
Gorlatov Sergey
Huang Ling
Rankin Christopher
Stavenhagen Jeffrey
Vijh Sujata
Auerbach Jeffrey I.
Crowder Chun
ESF, LLC
Haddad Maher M.
Macrogenics Inc.
LandOfFree
Identification and engineering of antibodies with variant Fc... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification and engineering of antibodies with variant Fc..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification and engineering of antibodies with variant Fc... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3913781